Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Ovarian Neoplasms

  Free Subscription


Articles published in Oncogene

Retrieve available abstracts of 83 articles:
HTML format



Single Articles


    May 2021
  1. TAN J, Zheng X, Li M, Ye F, et al
    C/EBPbeta promotes poly(ADP-ribose) polymerase inhibitor resistance by enhancing homologous recombination repair in high-grade serous ovarian cancer.
    Oncogene. 2021 May 8. pii: 10.1038/s41388-021-01788.
    PubMed     Abstract available


    April 2021
  2. LINDZEN M, Ghosh S, Noronha A, Drago D, et al
    Targeting autocrine amphiregulin robustly and reproducibly inhibits ovarian cancer in a syngeneic model: roles for wildtype p53.
    Oncogene. 2021 Apr 30. pii: 10.1038/s41388-021-01784.
    PubMed     Abstract available


    January 2021
  3. NOH K, Bach DH, Choi HJ, Kim MS, et al
    The hidden role of paxillin: localization to nucleus promotes tumor angiogenesis.
    Oncogene. 2021;40:384-395.
    PubMed     Abstract available


    October 2020
  4. ZHANG Q, Zhou W, Yu S, Ju Y, et al
    Metabolic reprogramming of ovarian cancer involves ACSL1-mediated metastasis stimulation through upregulated protein myristoylation.
    Oncogene. 2020 Oct 20. pii: 10.1038/s41388-020-01516.
    PubMed     Abstract available


  5. RANZUGLIA V, Lorenzon I, Pellarin I, Sonego M, et al
    Serum- and glucocorticoid- inducible kinase 2, SGK2, is a novel autophagy regulator and modulates platinum drugs response in cancer cells.
    Oncogene. 2020;39:6370-6386.
    PubMed     Abstract available


    September 2020
  6. XU Z, Li X, Li H, Nie C, et al
    Suppression of DDX39B sensitizes ovarian cancer cells to DNA-damaging chemotherapeutic agents via destabilizing BRCA1 mRNA.
    Oncogene. 2020 Sep 28. pii: 10.1038/s41388-020-01482.
    PubMed     Abstract available


  7. MEHNER C, Miller E, Hockla A, Coban M, et al
    Targeting an autocrine IL-6-SPINK1 signaling axis to suppress metastatic spread in ovarian clear cell carcinoma.
    Oncogene. 2020 Sep 14. pii: 10.1038/s41388-020-01451.
    PubMed     Abstract available


    July 2020
  8. NAIR J, Huang TT, Murai J, Haynes B, et al
    Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer.
    Oncogene. 2020 Jul 9. pii: 10.1038/s41388-020-1383.
    PubMed     Abstract available


    May 2020
  9. LI J, Alvero AB, Nuti S, Tedja R, et al
    CBX7 binds the E-box to inhibit TWIST-1 function and inhibit tumorigenicity and metastatic potential.
    Oncogene. 2020;39:3965-3979.
    PubMed     Abstract available


    April 2020
  10. PELLARIN I, Dall'Acqua A, Gambelli A, Pellizzari I, et al
    Splicing factor proline- and glutamine-rich (SFPQ) protein regulates platinum response in ovarian cancer-modulating SRSF2 activity.
    Oncogene. 2020 Apr 24. pii: 10.1038/s41388-020-1292.
    PubMed     Abstract available


  11. KAN T, Wang W, Ip PP, Zhou S, et al
    Single-cell EMT-related transcriptional analysis revealed intra-cluster heterogeneity of tumor cell clusters in epithelial ovarian cancer ascites.
    Oncogene. 2020 Apr 13. pii: 10.1038/s41388-020-1288.
    PubMed     Abstract available


    March 2020
  12. CHOI PW, So WW, Yang J, Liu S, et al
    MicroRNA-200 family governs ovarian inclusion cyst formation and mode of ovarian cancer spread.
    Oncogene. 2020 Mar 25. pii: 10.1038/s41388-020-1264.
    PubMed     Abstract available


  13. TAMURA R, Yoshihara K, Nakaoka H, Yachida N, et al
    XCL1 expression correlates with CD8-positive T cells infiltration and PD-L1 expression in squamous cell carcinoma arising from mature cystic teratoma of the ovary.
    Oncogene. 2020 Mar 2. pii: 10.1038/s41388-020-1237.
    PubMed     Abstract available


  14. HAYASHI T, Sano K, Aburatani H, Yaegashi N, et al
    Initialization of epithelial cells by tumor cells in a metastatic microenvironment.
    Oncogene. 2020;39:2638-2640.
    PubMed    


    February 2020
  15. CHEN C, Gupta P, Parashar D, Nair GG, et al
    ERBB3-induced furin promotes the progression and metastasis of ovarian cancer via the IGF1R/STAT3 signaling axis.
    Oncogene. 2020 Feb 6. pii: 10.1038/s41388-020-1194.
    PubMed     Abstract available


    January 2020
  16. KWEON J, Jang AH, Shin HR, See JE, et al
    A CRISPR-based base-editing screen for the functional assessment of BRCA1 variants.
    Oncogene. 2020;39:30-35.
    PubMed     Abstract available


    November 2019
  17. CLUZET V, Devillers MM, Petit F, Chauvin S, et al
    Aberrant granulosa cell-fate related to inactivated p53/Rb signaling contributes to granulosa cell tumors and to FOXL2 downregulation in the mouse ovary.
    Oncogene. 2019 Nov 19. pii: 10.1038/s41388-019-1109.
    PubMed     Abstract available


  18. KIM YS, Gupta Vallur P, Jones VM, Worley BL, et al
    Context-dependent activation of SIRT3 is necessary for anchorage-independent survival and metastasis of ovarian cancer cells.
    Oncogene. 2019 Nov 13. pii: 10.1038/s41388-019-1097.
    PubMed     Abstract available


  19. SUN C, Li X, Guo E, Li N, et al
    MCP-1/CCR-2 axis in adipocytes and cancer cell respectively facilitates ovarian cancer peritoneal metastasis.
    Oncogene. 2019 Nov 8. pii: 10.1038/s41388-019-1090.
    PubMed     Abstract available


  20. ASARE-WEREHENE M, Nakka K, Reunov A, Chiu CT, et al
    The exosome-mediated autocrine and paracrine actions of plasma gelsolin in ovarian cancer chemoresistance.
    Oncogene. 2019 Nov 7. pii: 10.1038/s41388-019-1087.
    PubMed     Abstract available


    September 2019
  21. TUNG CH, Kuo LW, Huang MF, Wu YY, et al
    MicroRNA-150-5p promotes cell motility by inhibiting c-Myb-mediated Slug suppression and is a prognostic biomarker for recurrent ovarian cancer.
    Oncogene. 2019 Sep 30. pii: 10.1038/s41388-019-1025.
    PubMed     Abstract available


  22. ZHAO L, Wang W, Xu L, Yi T, et al
    Correction: Integrative network biology analysis identifies miR-508-3p as the determinant for the mesenchymal identity and a strong prognostic biomarker of ovarian cancer.
    Oncogene. 2019 Sep 3. pii: 10.1038/s41388-019-0896.
    PubMed     Abstract available


  23. ZHANG MH, Zhang HH, Du XH, Gao J, et al
    UCHL3 promotes ovarian cancer progression by stabilizing TRAF2 to activate the NF-kappaB pathway.
    Oncogene. 2019 Sep 2. pii: 10.1038/s41388-019-0987.
    PubMed     Abstract available


    August 2019
  24. HAN Y, Kim B, Cho U, Park IS, et al
    Mitochondrial fission causes cisplatin resistance under hypoxic conditions via ROS in ovarian cancer cells.
    Oncogene. 2019 Aug 13. pii: 10.1038/s41388-019-0949.
    PubMed     Abstract available


    July 2019
  25. KLEINSCHMIDT EG, Miller NLG, Ozmadenci D, Tancioni I, et al
    Rgnef promotes ovarian tumor progression and confers protection from oxidative stress.
    Oncogene. 2019 Jul 15. pii: 10.1038/s41388-019-0881.
    PubMed     Abstract available


  26. HARDY LR, Pergande MR, Esparza K, Heath KN, et al
    Proteomic analysis reveals a role for PAX8 in peritoneal colonization of high grade serous ovarian cancer that can be targeted with micelle encapsulated thiostrepton.
    Oncogene. 2019 Jul 11. pii: 10.1038/s41388-019-0842.
    PubMed     Abstract available


  27. CHEN X, Mangala LS, Mooberry L, Bayraktar E, et al
    Identifying and targeting angiogenesis-related microRNAs in ovarian cancer.
    Oncogene. 2019 Jul 9. pii: 10.1038/s41388-019-0862.
    PubMed     Abstract available


  28. MAJEM B, Parrilla A, Jimenez C, Suarez-Cabrera L, et al
    MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC, WNT and AKT pathways.
    Oncogene. 2019 Jul 5. pii: 10.1038/s41388-019-0860.
    PubMed     Abstract available


    March 2019
  29. JEONG KJ, Park SY, Cho KH, Sohn JS, et al
    Correction: The Rho/ROCK pathway for lysophosphatidic acid-induced proteolytic enzyme expression and ovarian cancer cell invasion.
    Oncogene. 2019 Mar 29. pii: 10.1038/s41388-019-0769.
    PubMed     Abstract available


    February 2019
  30. JOHN B, Naczki C, Patel C, Ghoneum A, et al
    Regulation of the bi-directional cross-talk between ovarian cancer cells and adipocytes by SPARC.
    Oncogene. 2019 Feb 14. pii: 10.1038/s41388-019-0728.
    PubMed     Abstract available


  31. INESS AN, Felthousen J, Ananthapadmanabhan V, Sesay F, et al
    The cell cycle regulatory DREAM complex is disrupted by high expression of oncogenic B-Myb.
    Oncogene. 2019;38:1080-1092.
    PubMed     Abstract available


    January 2019
  32. HUANG CC, Cheng SH, Wu CH, Li WY, et al
    Delta-like 1 homologue promotes tumorigenesis and epithelial-mesenchymal transition of ovarian high-grade serous carcinoma through activation of Notch signaling.
    Oncogene. 2019 Jan 9. pii: 10.1038/s41388-018-0658.
    PubMed     Abstract available


  33. JING Y, Zhang Y, Zhu H, Zhang K, et al
    Hybrid sequencing-based personal full-length transcriptomic analysis implicates proteostatic stress in metastatic ovarian cancer.
    Oncogene. 2019 Jan 7. pii: 10.1038/s41388-018-0644.
    PubMed     Abstract available


    December 2018
  34. MOTOHARA T, Masuda K, Morotti M, Zheng Y, et al
    An evolving story of the metastatic voyage of ovarian cancer cells: cellular and molecular orchestration of the adipose-rich metastatic microenvironment.
    Oncogene. 2018 Dec 19. pii: 10.1038/s41388-018-0637.
    PubMed     Abstract available


  35. GRABOSCH S, Bulatovic M, Zeng F, Ma T, et al
    Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles.
    Oncogene. 2018 Dec 5. pii: 10.1038/s41388-018-0581.
    PubMed     Abstract available


    November 2018
  36. ZHAO L, Wang W, Xu L, Yi T, et al
    Integrative network biology analysis identifies miR-508-3p as the determinant for the mesenchymal identity and a strong prognostic biomarker of ovarian cancer.
    Oncogene. 2018 Nov 26. pii: 10.1038/s41388-018-0577.
    PubMed     Abstract available


    October 2018
  37. MCLEAN K, Tan L, Bolland DE, Coffman LG, et al
    Leukemia inhibitory factor functions in parallel with interleukin-6 to promote ovarian cancer growth.
    Oncogene. 2018 Oct 10. pii: 10.1038/s41388-018-0523.
    PubMed     Abstract available


    September 2018
  38. ZHONG Y, Yang S, Wang W, Wei P, et al
    The interaction of Lin28A/Rho associated coiled-coil containing protein kinase2 accelerates the malignancy of ovarian cancer.
    Oncogene. 2018 Sep 28. pii: 10.1038/s41388-018-0512.
    PubMed     Abstract available


    August 2018
  39. SUN J, Cai X, Yung MM, Zhou W, et al
    miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer.
    Oncogene. 2018 Aug 30. pii: 10.1038/s41388-018-0459.
    PubMed     Abstract available


    July 2018
  40. HODGKINSON K, Forrest LA, Vuong N, Garson K, et al
    GREB1 is an estrogen receptor-regulated tumour promoter that is frequently expressed in ovarian cancer.
    Oncogene. 2018 Jul 4. pii: 10.1038/s41388-018-0377.
    PubMed     Abstract available


  41. ZHOU W, Sun W, Yung MMH, Dai S, et al
    Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance.
    Oncogene. 2018;37:3981-3997.
    PubMed     Abstract available


    June 2018
  42. OZES AR, Pulliam N, Ertosun MG, Yilmaz O, et al
    Protein kinase A-mediated phosphorylation regulates STAT3 activation and oncogenic EZH2 activity.
    Oncogene. 2018;37:3589-3600.
    PubMed     Abstract available


    May 2018
  43. AL HABYAN S, Kalos C, Szymborski J, McCaffrey L, et al
    Multicellular detachment generates metastatic spheroids during intra-abdominal dissemination in epithelial ovarian cancer.
    Oncogene. 2018 May 23. pii: 10.1038/s41388-018-0317.
    PubMed     Abstract available


  44. GABBASOV R, Xiao F, Howe CG, Bickel LE, et al
    NEDD9 promotes oncogenic signaling, a stem/mesenchymal gene signature, and aggressive ovarian cancer growth in mice.
    Oncogene. 2018 May 18. pii: 10.1038/s41388-018-0296.
    PubMed     Abstract available


  45. RADA M, Nallanthighal S, Cha J, Ryan K, et al
    Inhibitor of apoptosis proteins (IAPs) mediate collagen type XI alpha 1-driven cisplatin resistance in ovarian cancer.
    Oncogene. 2018 May 17. pii: 10.1038/s41388-018-0297.
    PubMed     Abstract available


  46. BERNS K, Caumanns JJ, Hijmans EM, Gennissen AMC, et al
    ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.
    Oncogene. 2018 May 15. pii: 10.1038/s41388-018-0300.
    PubMed     Abstract available


    April 2018
  47. DORAYAPPAN KDP, Wanner R, Wallbillich JJ, Saini U, et al
    Hypoxia-induced exosomes contribute to a more aggressive and chemoresistant ovarian cancer phenotype: a novel mechanism linking STAT3/Rab proteins.
    Oncogene. 2018 Apr 11. pii: 10.1038/s41388-018-0189.
    PubMed     Abstract available


    February 2018
  48. MITAMURA T, Pradeep S, McGuire M, Wu SY, et al
    Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP).
    Oncogene. 2018;37:722-731.
    PubMed     Abstract available


  49. LIU Y, Zhou H, Zhu R, Ding F, et al
    SPSB3 targets SNAIL for degradation in GSK-3beta phosphorylation-dependent manner and regulates metastasis.
    Oncogene. 2018;37:768-776.
    PubMed     Abstract available


  50. LADANYI A, Mukherjee A, Kenny HA, Johnson A, et al
    Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis.
    Oncogene. 2018 Feb 5. pii: 10.1038/s41388-017-0093.
    PubMed     Abstract available


    January 2018
  51. AKHTER MZ, Sharawat SK, Kumar V, Kochat V, et al
    Aggressive serous epithelial ovarian cancer is potentially propagated by EpCAM(+)CD45(+) phenotype.
    Oncogene. 2018 Jan 30. pii: 10.1038/s41388-017-0106.
    PubMed     Abstract available


  52. GHANNAM-SHAHBARI D, Jacob E, Kakun RR, Wasserman T, et al
    PAX8 activates a p53-p21-dependent pro-proliferative effect in high grade serous ovarian carcinoma.
    Oncogene. 2018 Jan 30. pii: 10.1038/s41388-017-0040.
    PubMed     Abstract available


  53. RUSSO A, Czarnecki AA, Dean M, Modi DA, et al
    PTEN loss in the fallopian tube induces hyperplasia and ovarian tumor formation.
    Oncogene. 2018 Jan 25. pii: 10.1038/s41388-017-0097.
    PubMed     Abstract available


  54. GRITHER WR, Divine LM, Meller EH, Wilke DJ, et al
    TWIST1 induces expression of discoidin domain receptor 2 to promote ovarian cancer metastasis.
    Oncogene. 2018 Jan 19. pii: 10.1038/s41388-017-0043.
    PubMed     Abstract available


  55. NAGARAJ AB, Wang QQ, Joseph P, Zheng C, et al
    Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment.
    Oncogene. 2018;37:403-414.
    PubMed     Abstract available


  56. CORKERY DP, Clarke LE, Gebremeskel S, Salsman J, et al
    Loss of PRP4K drives anoikis resistance in part by dysregulation of epidermal growth factor receptor endosomal trafficking.
    Oncogene. 2018;37:174-184.
    PubMed     Abstract available


    October 2017
  57. WANG J, Kho DH, Zhou JY, Davis RJ, et al
    MKP-1 suppresses PARP-1 degradation to mediate cisplatin resistance.
    Oncogene. 2017;36:5939-5947.
    PubMed     Abstract available


    September 2017
  58. BIAN X, Gao J, Luo F, Rui C, et al
    PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
    Oncogene. 2017 Sep 25. doi: 10.1038/onc.2017.
    PubMed     Abstract available


  59. RAMADOSS S, Sen S, Ramachandran I, Roy S, et al
    Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.
    Oncogene. 2017 Sep 18. doi: 10.1038/onc.2017.
    PubMed     Abstract available


  60. YAMAGUCHI H, Du Y, Nakai K, Ding M, et al
    EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.
    Oncogene. 2017 Sep 18. doi: 10.1038/onc.2017.
    PubMed     Abstract available


  61. GUO H, Zhu Q, Yu X, Merugu SB, et al
    Tumor-secreted anterior gradient-2 binds to VEGF and FGF2 and enhances their activities by promoting their homodimerization.
    Oncogene. 2017;36:5098-5109.
    PubMed     Abstract available


    August 2017
  62. SOMASAGARA RR, Spencer SM, Tripathi K, Clark DW, et al
    RAD6 promotes DNA repair and stem cell signaling in ovarian cancer and is a promising therapeutic target to prevent and treat acquired chemoresistance.
    Oncogene. 2017 Aug 14. doi: 10.1038/onc.2017.
    PubMed     Abstract available


    June 2017
  63. TO SKY, Mak ASC, Eva Fung YM, Che CM, et al
    beta-catenin downregulates Dicer to promote ovarian cancer metastasis.
    Oncogene. 2017 Jun 26. doi: 10.1038/onc.2017.
    PubMed     Abstract available


  64. KLYMENKO Y, Kim O, Loughran E, Yang J, et al
    Cadherin composition and multicellular aggregate invasion in organotypic models of epithelial ovarian cancer intraperitoneal metastasis.
    Oncogene. 2017 Jun 19. doi: 10.1038/onc.2017.
    PubMed     Abstract available


    May 2017
  65. ZHAO J, Wang Y, Mu C, Xu Y, et al
    MAGEA1 interacts with FBXW7 and regulates ubiquitin ligase-mediated turnover of NICD1 in breast and ovarian cancer cells.
    Oncogene. 2017 May 1. doi: 10.1038/onc.2017.
    PubMed     Abstract available


    April 2017
  66. NIU N, Mercado-Uribe I, Liu J
    Dedifferentiation into blastomere-like cancer stem cells via formation of polyploid giant cancer cells.
    Oncogene. 2017 Apr 24. doi: 10.1038/onc.2017.
    PubMed     Abstract available


    March 2017
  67. SHANG Y, He J, Wang Y, Feng Q, et al
    CHIP/Stub1 regulates the Warburg effect by promoting degradation of PKM2 in ovarian carcinoma.
    Oncogene. 2017 Mar 27. doi: 10.1038/onc.2017.
    PubMed     Abstract available


  68. BASULI D, Tesfay L, Deng Z, Paul B, et al
    Iron addiction: a novel therapeutic target in ovarian cancer.
    Oncogene. 2017 Mar 20. doi: 10.1038/onc.2017.
    PubMed     Abstract available


  69. COMISSO E, Scarola M, Rosso M, Piazza S, et al
    OCT4 controls mitotic stability and inactivates the RB tumor suppressor pathway to enhance ovarian cancer aggressiveness.
    Oncogene. 2017 Mar 20. doi: 10.1038/onc.2017.
    PubMed     Abstract available


  70. GUPTA R, Yang Q, Dogra SK, Wajapeyee N, et al
    Serine hydroxymethyl transferase 1 stimulates pro-oncogenic cytokine expression through sialic acid to promote ovarian cancer tumor growth and progression.
    Oncogene. 2017 Mar 13. doi: 10.1038/onc.2017.
    PubMed     Abstract available


    February 2017
  71. HWANG MH, Cho KH, Jeong KJ, Park YY, et al
    RCP induces Slug expression and cancer cell invasion by stabilizing beta1 integrin.
    Oncogene. 2017;36:1102-1111.
    PubMed     Abstract available


  72. HARJES U, Bridges E, Gharpure KM, Roxanis I, et al
    Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4.
    Oncogene. 2017;36:912-921.
    PubMed     Abstract available


  73. LAU TS, Chan LK, Wong EC, Hui CW, et al
    A loop of cancer-stroma-cancer interaction promotes peritoneal metastasis of ovarian cancer via TNFalpha-TGFalpha-EGFR.
    Oncogene. 2017 Feb 6. doi: 10.1038/onc.2016.
    PubMed     Abstract available


    January 2017
  74. ZHAO L, Ji G, Le X, Luo Z, et al
    An integrated analysis identifies STAT4 as a key regulator of ovarian cancer metastasis.
    Oncogene. 2017 Jan 23. doi: 10.1038/onc.2016.
    PubMed     Abstract available


    December 2016
  75. MODI DA, Tagare RD, Karthikeyan S, Russo A, et al
    PAX2 function, regulation and targeting in fallopian tube-derived high-grade serous ovarian cancer.
    Oncogene. 2016 Dec 19. doi: 10.1038/onc.2016.
    PubMed     Abstract available


  76. GURLER MAIN H, Xie J, Muralidhar GG, Elfituri O, et al
    Emergent role of the fractalkine axis in dissemination of peritoneal metastasis from epithelial ovarian carcinoma.
    Oncogene. 2016 Dec 12. doi: 10.1038/onc.2016.
    PubMed     Abstract available


    November 2016
  77. WILSON C, Qiu L, Hong Y, Karnik T, et al
    The histone demethylase KDM4B regulates peritoneal seeding of ovarian cancer.
    Oncogene. 2016 Nov 21. doi: 10.1038/onc.2016.
    PubMed     Abstract available


  78. DIMITROVA N, Nagaraj AB, Razi A, Singh S, et al
    InFlo: a novel systems biology framework identifies cAMP-CREB1 axis as a key modulator of platinum resistance in ovarian cancer.
    Oncogene. 2016 Nov 7. doi: 10.1038/onc.2016.
    PubMed     Abstract available


    October 2016
  79. MATSUURA K, Huang NJ, Cocce K, Zhang L, et al
    Downregulation of the proapoptotic protein MOAP-1 by the UBR5 ubiquitin ligase and its role in ovarian cancer resistance to cisplatin.
    Oncogene. 2016 Oct 10. doi: 10.1038/onc.2016.
    PubMed     Abstract available


  80. RAMADOSS S, Sen S, Ramachandran I, Roy S, et al
    Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.
    Oncogene. 2016 Oct 3. doi: 10.1038/onc.2016.
    PubMed     Abstract available


  81. WITT AE, Lee CW, Lee TI, Azzam DJ, et al
    Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer.
    Oncogene. 2016 Oct 3. doi: 10.1038/onc.2016.
    PubMed     Abstract available


    September 2016
  82. FANG D, Chen H, Zhu JY, Wang W, et al
    Epithelial-mesenchymal transition of ovarian cancer cells is sustained by Rac1 through simultaneous activation of MEK1/2 and Src signaling pathways.
    Oncogene. 2016 Sep 12. doi: 10.1038/onc.2016.
    PubMed     Abstract available


    June 2016
  83. DE CIAN MC, Pauper E, Bandiera R, Vidal VP, et al
    Amplification of R-spondin1 signaling induces granulosa cell fate defects and cancers in mouse adult ovary.
    Oncogene. 2016 Jun 6. doi: 10.1038/onc.2016.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: